Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Abpro (NASDAQ:ABP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares Aprea Therapeutics and Abpro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | -2,666.46% | -88.12% | -68.78% |
| Abpro | N/A | N/A | -344.76% |
Institutional and Insider Ownership
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 13.7% of Abpro shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aprea Therapeutics | $1.50 million | 5.09 | -$12.96 million | ($2.15) | -0.56 |
| Abpro | $180,000.00 | 104.12 | -$7.23 million | ($4.23) | -1.63 |
Abpro has lower revenue, but higher earnings than Aprea Therapeutics. Abpro is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Aprea Therapeutics and Abpro, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 1 | 0 | 2 | 0 | 2.33 |
| Abpro | 1 | 1 | 0 | 0 | 1.50 |
Aprea Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 1,180.99%. Abpro has a consensus price target of $120.00, suggesting a potential upside of 1,641.65%. Given Abpro’s higher probable upside, analysts clearly believe Abpro is more favorable than Aprea Therapeutics.
Risk and Volatility
Aprea Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Abpro has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.
Summary
Aprea Therapeutics beats Abpro on 8 of the 14 factors compared between the two stocks.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
About Abpro
Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
